Artivion (AORT) Competitors $31.08 -0.16 (-0.50%) Closing price 03:59 PM EasternExtended Trading$31.06 -0.03 (-0.10%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AORT vs. BLCO, IRTC, SLNO, TMDX, INSP, NVST, PRCT, WRBY, LIVN, and EYEShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Inspire Medical Systems (INSP), Envista (NVST), PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), LivaNova (LIVN), and National Vision (EYE). These companies are all part of the "medical equipment" industry. Artivion vs. Its Competitors Bausch + Lomb iRhythm Technologies Soleno Therapeutics TransMedics Group Inspire Medical Systems Envista PROCEPT BioRobotics Warby Parker LivaNova National Vision Bausch + Lomb (NYSE:BLCO) and Artivion (NYSE:AORT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is BLCO or AORT more profitable? Artivion has a net margin of -5.49% compared to Bausch + Lomb's net margin of -7.50%. Artivion's return on equity of 3.63% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-7.50% 2.62% 1.28% Artivion -5.49%3.63%1.34% Do institutionals & insiders believe in BLCO or AORT? 11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Comparatively, 7.6% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, BLCO or AORT? Bausch + Lomb has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Does the media refer more to BLCO or AORT? In the previous week, Artivion had 1 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Artivion and 5 mentions for Bausch + Lomb. Artivion's average media sentiment score of 0.91 beat Bausch + Lomb's score of 0.58 indicating that Artivion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BLCO or AORT? Bausch + Lomb currently has a consensus price target of $15.45, suggesting a potential upside of 9.96%. Artivion has a consensus price target of $32.40, suggesting a potential upside of 4.23%. Given Bausch + Lomb's higher possible upside, equities research analysts clearly believe Bausch + Lomb is more favorable than Artivion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has preferable earnings & valuation, BLCO or AORT? Artivion has lower revenue, but higher earnings than Bausch + Lomb. Artivion is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.79B1.04-$317M-$1.03-13.65Artivion$388.54M3.42-$13.36M-$0.50-62.17 SummaryArtivion beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks. Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$1.33B$6.86B$5.70B$21.16BDividend YieldN/A1.27%4.59%3.57%P/E Ratio-62.1718.3220.9824.41Price / Sales3.4264.59443.3258.80Price / Cash37.4420.6736.5523.00Price / Book4.724.728.634.67Net Income-$13.36M$176.14M$3.24B$993.85M7 Day Performance0.77%1.68%3.22%1.16%1 Month Performance-0.06%3.77%10.72%4.99%1 Year Performance10.94%6.45%34.94%12.54% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion2.9247 of 5 stars$31.09-0.5%$32.40+4.2%+11.8%$1.33B$388.54M-62.171,600News CoverageBLCOBausch + Lomb2.1922 of 5 stars$13.67-1.5%$15.45+13.1%-16.3%$4.83B$4.83B-13.2713,500News CoverageUpcoming EarningsIRTCiRhythm Technologies1.3141 of 5 stars$138.91+2.2%$138.60-0.2%+34.4%$4.43B$591.84M-44.242,000Positive NewsUpcoming EarningsSLNOSoleno Therapeutics3.7846 of 5 stars$82.76+1.5%$108.70+31.3%+80.7%$4.17BN/A-17.9130Positive NewsHigh Trading VolumeTMDXTransMedics Group2.3525 of 5 stars$116.88+3.9%$127.33+8.9%-29.2%$3.95B$441.54M85.94210Positive NewsUpcoming EarningsINSPInspire Medical Systems4.9002 of 5 stars$130.17-0.1%$211.91+62.8%-5.3%$3.84B$802.80M59.981,246Positive NewsAnalyst ForecastNVSTEnvista3.5158 of 5 stars$20.05-0.8%$20.23+0.9%+27.8%$3.40B$2.51B-3.0712,300Upcoming EarningsPRCTPROCEPT BioRobotics2.7815 of 5 stars$58.17+2.7%$87.50+50.4%-13.5%$3.22B$249.12M-34.22430Upcoming EarningsWRBYWarby Parker2.6956 of 5 stars$23.02+3.7%$22.88-0.6%+47.4%$2.41B$795.09M-191.803,780News CoverageInsider TradeLIVNLivaNova3.3354 of 5 stars$43.97-0.8%$59.29+34.8%-19.2%$2.40B$1.25B-10.752,900Upcoming EarningsEYENational Vision2.8177 of 5 stars$25.01+2.2%$22.10-11.6%+91.6%$1.98B$1.82B-75.7913,411Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Bausch + Lomb Competitors iRhythm Technologies Competitors Soleno Therapeutics Competitors TransMedics Group Competitors Inspire Medical Systems Competitors Envista Competitors PROCEPT BioRobotics Competitors Warby Parker Competitors LivaNova Competitors National Vision Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AORT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
